Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: A multi-center study

Journal of Neuro-Oncology

Volumn 108, Issue 3, 2012, Pages 491-498

  Pope, Whitney B ^a   Qiao, Xin Joe ^a   Kim, Hyun J ^a   Lai, Albert ^a   Nghiemphu, Phioanh ^a   Xue, Xi ^a   Ellingson, Benjamin M ^a   Schiff, David ^b   Aregawi, Dawit ^c   Cha, Soonmee ^d   Puduvalli, Vinay K ^e   Wu, Jing ^e   Yung, Wai Kwan A ^e   Young, Geoffrey S ^f   Vredenburgh, James ^g   Barboriak, Dan ^g   Abrey, Lauren E ^h   Mikkelsen, Tom ⁱ   Jain, Rajan ⁱ   Paleologos, Nina A ^j   Rn, Patricia Lada ^j   Prados, Michael ^d   Goldin, Jonathan ^a   Wen, Patrick Y ^f   Cloughesy, Timothy ^a   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ HENRY FORD HOSPITAL   (United States)

^j NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

more..

Author keywords

Apparent diffusion coefficient; Glioblastoma multiforme; Progression free survival

Indexed keywords

BEVACIZUMAB; IRINOTECAN;

ADULT; AGED; APPARENT DIFFUSION COEFFICIENT; ARTICLE; CLASSIFIER; CONFIDENCE INTERVAL; DIFFUSION COEFFICIENT; FEMALE; GLIOBLASTOMA; HAZARD RATIO; HISTOGRAM; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POST HOC ANALYSIS; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; TUMOR GROWTH; TUMOR RECURRENCE;

ADULT; AGED; ALGORITHMS; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

EID: 84864051629     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-0847-y     Document Type: Article

References (23)

1. Herbert C, Williams M, Sawyer H et al (2011) Treatment of Glioblastoma Multiforme with radiotherapy and concomitant and adjuvant temozolomide: translation ofrandomised controlled trial evidence into routine clinical practice. Clin Oncol 27:372-373
2. Lamborn KR, Yung WK, Chang SM et al (2008) Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 10:162-170
3. Macdonald DR, Cascino TL, Schold SC Jr et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280 (Pubitemid 20195640)
4. Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28: 1963-1972
5. Norden AD, Young GS, Setayesh K et al (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779-787
6. Weller M, Wick W, Hegi ME et al (2010) Should biomarkers be used to design personalized medicine for the treatment of glio-blastoma? Future Oncol 6:1407-1414
7. Bode MK, Ruohonen J, Nieminen MT et al (2006) Potential of diffusion imaging in brain tumors: a review. Acta Radiol 47: 585-594 (Pubitemid 44000710)
8. Ellingson BM, Malkin MG, Rand SD et al (2010) Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging 31:538-548
9. Chenevert TL, Sundgren PC, Ross BD (2006) Diffusion imaging: insight to cell status and cytoarchitecture. Neuroimaging Clin N Am 16:619-632, viii-ix (Pubitemid 44828754)
10. Pope WB, Kim HJ, Huo J et al (2009) Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bev-acizumab treatment. Radiology 252:182-189
11. Jain R, Scarpace LM, Ellika S et al (2010) Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker. J Neuro Oncol 96:423-431
12. Nowosielski M, Recheis W, Goebel G et al (2011) ADC histo-grams predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma. Neuroradiology 53:291-302
13. Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblas-toma. J Clin Oncol 27:4733-4740
14. Prados M, Cloughesy T, Samant M et al (2011) Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol 13:143-151
15. Batchelor TT, Sorensen AG, di Tomaso E et al (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83-95 (Pubitemid 46075199)
16. Ellingson BM, Cloughesy TF, Lai A et al (2011) Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. Neuro Oncol 13:401-409
17. Pope WB, Young JR, Ellingson BM (2011) Advances in MRI assessment of gliomas and response to anti-VEGF therapy. Curr Neurol Neurosci Rep 11:336-344
18. Chamberlain MC, Glantz MJ, Chalmers L et al (2007) Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neuro Oncol 82:81-83
19. Sanghera P, Perry J, Sahgal A et al (2010) Pseudoprogression following chemoradiotherapy for glioblastoma multiforme. Can J Neuro Sci 37:36-42
20. Brandsma D, van den Bent MJ (2009) Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol 22:633-638
21. Bedekar D, Jensen T, Schmainda KM (2010) Standardization of relative cerebral blood volume (rCBV) image maps for ease of both inter- and intrapatient comparisons. Magn Reson Med 64:907-913
22. Ashton E (2010) Quantitative MR in multi-center clinical trials. J Magn Reson Imaging 31:279-288
23. Sorensen AG, Batchelor TT, Zhang WT et al (2009) A ''vascular normalization index'' as potential mechanistic biomarker to pre-dict survival after a single dose of cediranib in recurrent glio-blastoma patients. Cancer Res 69:5296-5300